Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

PURPOSE: Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth factor receptor 2 (HER2) positive. Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility study of trastuzumab and pertuzumab added to neo...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Clin Oncol
Κύριοι συγγραφείς: Stroes, Charlotte I., Schokker, Sandor, Creemers, Aafke, Molenaar, Remco J., Hulshof, Maarten C.C.M., van der Woude, Stephanie O., Bennink, Roel J., Mathôt, Ron A.A., Krishnadath, Kausilia K., Punt, Cornelis J.A., Verhoeven, Rob H.A., van Oijen, Martijn G.H., Creemers, Geert-Jan, Nieuwenhuijzen, Grard A.P., van der Sangen, Maurice J.C., Beerepoot, Laurens V., Heisterkamp, Joos, Los, Maartje, Slingerland, Marije, Cats, Annemieke, Hospers, Geke A.P., Bijlsma, Maarten F., van Berge Henegouwen, Mark I., Meijer, Sybren L., van Laarhoven, Hanneke W.M.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2020
Θέματα:
ORIGINAL REPORTS
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007286/
https://ncbi.nlm.nih.gov/pubmed/31809243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01814
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια